RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
When a drug is put on the market, it may not perform exactly the same way as it did at prior to obtaining market authorisation (namely, at the clinical research stage or during the pricing negotiation). This risk is now covered by a “conditio- nal contract”. A quick agreement on the price is granted provided pharmaceuti- cal companies undertake to partially or fully refund the sum initially negotiated should the treatment be less effective than originally stated. Using a framework setting out application guidelines, we shall analyse these market access contracts for reimbursable products under the Social Security system. For the most part, these conditional contracts are drawn up on the strength of descriptive or nor- mative studies without a control group. This means that the therapeutic impact of the drug cannot be measured. In such a context, price xing for drugs may be jeopardised by the scanty quality of evidence. In order to address this issue, we suggest setting up comparative observational studies and comparing groups with the appropriate micro-econometric studies.